TransMedics (TMDX) Q3 2026 Earnings Call Transcript

TransMedics (TMDX) reported Q3 2026 revenue of $203M, up 41% YoY. Transplant product revenue grew 29% YoY to $113M, while service revenue increased 44% YoY to $79M. The company expects growth to accelerate due to ongoing initiatives. Cash reserves totaled $493M. TransMedics advanced clinical programs for heart and lung transplants, with FDA approvals for key studies. European expansion and kidney transplant developments are also underway.

Original reporting
Published Nov 6, 2026, 6:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 6:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TransMedics (TMDX) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$TMDXBullishMed
01

Why it matters

Earnings beat and cash buildup support near‑term upside, but upcoming clinical trial outcomes remain a risk.

02

Market read

First earnings report of the quarter; provides fresh data for traders targeting niche biotech stocks.

03

What to watch

Future cash burn from upcoming clinical programs and European expansion could pressure balance sheet.

Relevance 6/10Novelty 7/10Timing: post‑earnings release today

Background

TransMedics provides normothermic organ perfusion systems for transplant logistics.

Company-level read

Ticker impact

$TMDXBullishHigh confidence
Context

Q3 2026 earnings release showing $203M revenue, 41% YoY growth and cash balance of $493M.

Expected impact

likely upside as investors price in higher revenue growth and cash strength

Evidence & confidence

Revenue beat expectations and cash buildup typically drive short-term buying pressure for micro‑cap stocks.

Market effects

Highlights growth potential in organ‑preservation market, may boost related biotech and medical device peers.

U.S. biotech sector sees a positive data point; European expansion noted but limited immediate effect.

Limited to niche transplant logistics space; no broad market impact.

Counterpoint

Micro‑cap valuation may already price in growth; any miss on upcoming FDA approvals could reverse gains.

Key entities

  • TransMedics

    Medical device company focused on organ preservation.

Related articles

Med

TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.